Based on the treatment guideline: weak recommendation for starting SGLT2 inhibitors and GLP-1 receptor agonists for patients with established CVD or CKD, this study showed that a moderate proportion of the physicians (56%) adhered to the guidelines for diabetes management for patients with ASCVD because the prescription of SGLT2 inhibitors and GLP-1 receptor agonists are not strongly recommended. The gene discussed is GLP1R; the disease is chronic kidney disease.